Literature DB >> 10352857

Eradication of vaccine-preventable diseases.

A Hinman1.   

Abstract

Eradication is the permanent reduction to zero of the worldwide incidence of infection caused by a specific agent as a result of deliberate efforts; intervention measures are no longer needed. To date, the only infectious disease that has been eradicated is smallpox. Poliomyelitis is targeted for eradication by the year 2000, and the eradication initiative is well under way, with the Western Hemisphere certified as being polio-free and more than one year having passed since polio cases occurred in the Western Pacific Region of the World Health Organization. A review of the technical feasibility of eradicating other diseases preventable by vaccines currently licensed for civilian use in the United States indicates that measles, hepatitis B, mumps, rubella, and possibly disease caused by Haemophilus influenzae type b are potential candidates. From a practical point of view, measles seems most likely to be the next target. Global capacity to undertake eradication is limited, and care must be taken to ensure that a potential measles eradication effort does not impede achievement of polio eradication. Even in the absence of eradication, major improvements in control are both feasible and necessary with existing vaccines. New and improved vaccines may give further possibilities of eradication in the future. Eradication represents the ultimate in sustainability and social justice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352857     DOI: 10.1146/annurev.publhealth.20.1.211

Source DB:  PubMed          Journal:  Annu Rev Public Health        ISSN: 0163-7525            Impact factor:   21.981


  18 in total

1.  Evaluation of the cold-chain for oral polio vaccine in a rural district of India.

Authors:  Yogindra Samant; Hemant Lanjewar; David Parker; Lester Block; Gajendra S Tomar; Ben Stein
Journal:  Public Health Rep       Date:  2007 Jan-Feb       Impact factor: 2.792

2.  The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Medscape J Med       Date:  2008-08-13

3.  New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population.

Authors:  P Plans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-16       Impact factor: 3.267

4.  Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study.

Authors:  A Domínguez; P Plans; J Costa; N Torner; N Cardenosa; J Batalla; A Plasencia; L Salleras
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-05       Impact factor: 3.267

Review 5.  Prevention strategies for herpes zoster and post-herpetic neuralgia.

Authors:  Myron J Levin; Anne A Gershon; Robert H Dworkin; Marc Brisson; Lawrence Stanberry
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

6.  Impact of COVID-19 on vaccination programs: adverse or positive?

Authors:  Inayat Ali
Journal:  Hum Vaccin Immunother       Date:  2020-09-22       Impact factor: 3.452

7.  A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.

Authors:  Jorge Reyes del Valle; Patricia Devaux; Gregory Hodge; Nicholas J Wegner; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 8.  The role of research in viral disease eradication and elimination programs: lessons for malaria eradication.

Authors:  Joel G Breman; Ciro A de Quadros; Walter R Dowdle; William H Foege; Donald A Henderson; T Jacob John; Myron M Levine
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

9.  'Communicate to vaccinate' (COMMVAC). building evidence for improving communication about childhood vaccinations in low- and middle-income countries: protocol for a programme of research.

Authors:  Simon Lewin; Sophie Hill; Leyla H Abdullahi; Sara Bensaude de Castro Freire; Xavier Bosch-Capblanch; Claire Glenton; Gregory D Hussey; Catherine M Jones; Jessica Kaufman; Vivian Lin; Hassan Mahomed; Linda Rhoda; Priscilla Robinson; Zainab Waggie; Natalie Willis; Charles S Wiysonge
Journal:  Implement Sci       Date:  2011-12-02       Impact factor: 7.327

Review 10.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.